The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment

Wilson Disease Clinical Trial

Official title:

Multi-Center Study for the Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02763215
• Other study ID #: WTX101-203
• Status: Completed
• Start date: May 19, 2016
• Est. completion date: January 21, 2019

Study information

• Verified date: November 2020
• Source: Alexion Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications.

After providing informed consent, participants meeting all inclusion and no exclusion criteria were enrolled into the study as outpatients. The participants' routine clinic visits were scheduled according to the standard clinical practice at the study center and at the discretion of the treating physician at approximate 6-month intervals.

At the time of enrollment, participants were receiving SoC medications for the treatment of WD, which could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc. If treatment was interrupted or stopped during the course of the study, participants continued in the study and biological samples and clinical data were continued to be collected for the full 24-month study period. Dosing with SoC agents was individualized and managed by the treating physician at the study center according to standard clinical practice at the site.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: January 21, 2019
• Est. primary completion date: January 21, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing and able to give informed consent for participation in the study.

• Male or female participants, aged 18 years or older as of signing the informed consent form.

• Receiving SoC medications (penicillamine, trientine, zinc, or copper chelators with zinc) for the treatment of WD at the time of enrollment and for no more than 60 months prior to enrollment.

• Able to understand and willing to comply with study procedures and requirements, as judged by the Investigator.

• Established diagnosis of WD.

• Adequate venous access to allow for collection of blood samples.

Exclusion Criteria:

• Major systemic disease or other illness that would, in the opinion of the Investigator, compromise participant safety or interfere with the collection or interpretation of study results.

• In the opinion of the Investigator, the participant was likely to be non-compliant or uncooperative during the study.

Related Conditions & MeSH terms

• Wilson Disease

Intervention

Drug:
• Standard of Care Medications
Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.

Locations

Country	Name	City	State
Austria	Clinical Trial Site	Vienna
Germany	Clinical Trial Site	Heidelberg
Poland	Clinical Trial Site	Warszawa
United Kingdom	Clinical Trial Site	Birmingham
United Kingdom	Clinical Trial Site	Guildford
United States	Clinical Trial Site	Ann Arbor	Michigan
United States	Clinical Trial Site	Chicago	Illinois
United States	Clinical Trial Site	Nashville	Tennessee
United States	Clinical Trial Site	New Haven	Connecticut
United States	Clinical Trial Site	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Alexion Pharmaceuticals

Countries where clinical trial is conducted

United States,  Austria,  Germany,  Poland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of Non-ceruloplasmin-bound Copper (NCC) Or Reached A Reduction Of = 25% In NCC During 6 Months Of Treatment	To achieve a normalized NCC concentration, participants must have had 2 consecutive measures within (or below) the normal concentration range (0.8 to 2.3 micromolar [µM]). Two consecutive measurements required that the measurements occurred on separate dates and were assigned to 2 different visits. Non-ceruloplasmin-bound copper was calculated by subtracting the amount of copper bound to the ceruloplasmin from the total plasma copper concentration.	Baseline through Month 6
Secondary	Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of NCC Or Reached A Reduction Of = 25% In NCC Through Last Assessment	To achieve a normalized NCC concentration, participants must have 2 consecutive measures within (or below) the normal range (0.8 to 2.3 µM). Two consecutive measurements required that the measurements occurred on separate dates and were assigned to 2 different visits. Non-ceruloplasmin-bound copper was calculated by subtracting the amount of copper bound to the ceruloplasmin from the total plasma copper concentration. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In NCC Concentrations At Month 6, Month 24, And Last Assessment	Evaluation of NCC concentrations over time are reported as micromoles/liter (µmol/L). Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Time To Normalization Of NCC If Above The Reference Range At The Time Of Enrollment	The time to normalization of NCC was measured by Kaplan-Meier analysis.	Baseline, up to 24 months
Secondary	Change From Baseline In Exchangeable Copper At Month 6, Month 24, And Last Assessment	The change in exchangeable copper was evaluated over time and is reported as nanograms/milliliter (ng/mL). Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Copper Plasma Ultrafiltrate At Month 6, Month 24, And Last Assessment	Change in copper plasma ultrafiltrate was measured over time and is reported as ng/mL. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Plasma Total Copper Used To Calculate NCC At Month 6, Month 24, And Last Assessment	Plasma total copper was measured over time and is reported as ng/mL. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Serum Total Ceruloplasmin (Nephelometry) Used To Calculate NCC At Month 6, Month 24, And Last Assessment	The total serum (nephelometry) was measured over time and is reported as milligrams (mg)/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In 24-Hour Urinary Copper At Month 6, Month 24, And Last Assessment	Evaluation of 24-hour urinary copper over time is reported as micrograms (µg)/day. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Plasma Total Molybdenum At Month 6 And Month 24	The plasma total molybdenum was measured over time and is reported in ng/mL.	Baseline, Month 6, Month 24
Secondary	Change From Baseline In Molybdenum Plasma Ultrafiltrate At Month 6 And Month 24	The molybdenum plasma ultrafiltrate was measured over time and is reported as ng/mL.	Baseline, Month 6, Month 24
Secondary	Change From Baseline In 24-Hour Urinary Molybdenum At Month 6 And Month 24	Evaluation of 24-hour urinary molybdenum over time is reported as µg/day.	Baseline, Month 6, Month 24
Secondary	Change From Baseline In Hepatic Laboratory Measures For Alanine Aminotransferase (ALT) At Month 6, Month 24, And Last Assessment	The ALT levels were measured over time and are reported as units (U)/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Hepatic Laboratory Measures For Aspartate Aminotransferase (AST) At Month 6, Month 24, And Last Assessment	The AST levels were measured over time and are reported as U/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Hepatic Laboratory Measures For Bilirubin At Month 6, Month 24, And Last Assessment	Bilirubin was measured over time and is reported as µmol/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Hepatic Laboratory Measures For International Normalized Ratio (INR) At Month 6, Month 24, And Last Assessment	The INR was measured over time. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	Change From Baseline In Clinical Global Impression (CGI) Scale Item 1 (Severity Of Illness) At Month 6, Month 24, And Last Assessment	The CGI scale item 1 (severity of illness) rating scale is a commonly used measure of symptom severity, treatment response, and the efficacy of treatments in treatment studies of participants with mental disorders. It uses the Clinical Global Impression - Severity Scale (CGI-S), a 7-point scale that requires the Investigator to rate the severity of the participant's illness at the time of assessment, relative to the Investigator's past experience with participants who had the same diagnosis. Considering total clinical experience, a participant was assessed on severity of illness at the time of rating as: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. A decrease in score indicates improvement in disease severity. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)
Secondary	CGI Scale Item 2 (Global Improvement) At Month 6, Month 24, And Last Assessment	The CGI scale item 2 (global improvement) is a rating scale commonly used measure of symptom severity, treatment response, and the efficacy of treatments in treatment studies of participants with mental disorders. It uses the Clinical Global Impression - Improvement Scale (CGI-I), a 7-point scale that requires the Investigator to assess how much the participant's illness has improved or worsened relative to the Baseline state at the beginning of the study and rate as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. A decrease in score indicates improvement in disease severity. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months).	Baseline through Last Assessment (ranging from 1 to 24 months)